The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

Background: Insulin degludec/liraglutide (IDegLira) results in glycated hemoglobin (HbA1c) levels comparable with basal-bolus (BB) therapy. Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes science and technology 2021-05, Vol.15 (3), p.636-645
Hauptverfasser:	Billings, Liana K., Agner, Bue F. Ross, Altuntas, Yuksel, Grøn, Randi, Halladin, Natalie, Klonoff, David C., Tentolouris, Nikolaos, Jódar, Esteban
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Blood Glucose Diabetes Mellitus, Type 2 - drug therapy Drug Combinations Glycated Hemoglobin A - analysis Humans Hypoglycemic Agents - therapeutic use Insulin Glargine Insulin, Long-Acting - therapeutic use Liraglutide - therapeutic use Middle Aged Original Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: Insulin degludec/liraglutide (IDegLira) results in glycated hemoglobin (HbA1c) levels comparable with basal-bolus (BB) therapy. Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics. Materials and Methods: DUAL VII trial participants (type 2 diabetes [T2D], HbA1c 53-86 mmol/mol [7.0%-10.0%]) were subgrouped post hoc based on the following baseline characteristics: HbA1c (≤58.5, >58.5 to ≤69.4, and >69.4 mmol/mol; ≤7.5%, >7.5 to ≤8.5%, and >8.5%), body mass index (
ISSN:	1932-2968 1932-2968 1932-3107
DOI:	10.1177/1932296820906888